Longevity and DeSci Recap – May 2024

Events, investment news, and innovations all happened in May.

In this latest edition of the Longevity and DeSci Recap, we’ll take a look back at May’s events, research, and investments to give you the latest update on what’s going on in the Longevity and DeSci world.

As the weather is heating up, so too are events surrounding longevity. Not only are there four great conferences coming up in the next few months, but organizations across the globe are securing funding, producing research, and getting results.

Tech breakthroughs & new research

Female-led biotech announces new innovative fertility research

Gameto, a biotech company focused on women’s health, recently announced novel research into cellular engineering and manufacturing techniques behind its proprietary solution Fertilo. This study looks into how ovarian support cells enhance in vitro fertilization (IVF) outcomes in an effort to improve further understanding of fertility issues.

AI heart care is here

This May, Caristo Diagnostics published a study in The Lancet on inflammatory risk and cardiovascular events in patients without obstructive coronary artery disease. What makes this study unique is that it draws on AI technology to assess cardiac risk utilizing its CaRi-Heart? technology, which the company claims can predict cardiac events due to coronary inflammation up to 10 years in advance. This could be a game-changer for heart care.

Innovative liver treatment on the horizon?

Immorta Bio Inc, a longevity company, announced its positive results with a new liver treatment using PMSC-11 stem cell therapy. The proprietary technology behind the solution resulted in a significant suppression of liver damage in a carbon tetrachloride model, preserving albumin production and preventing spikes in liver enzymes. Due to these results, the company is now seeking further preclinical trials before proceeding to FDA approval for clinical trials.

Read More on Lifespan.io...